Premium
New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation
Author(s) -
Yong Michelle K.,
Gottlieb David,
Lindsay Julian,
Kok Jen,
Rawlinson William,
Slavin Monica,
Ritchie David,
Bajel Ashish,
Grigg Andrew
Publication year - 2020
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14462
Subject(s) - medicine , cytomegalovirus , transplantation , stem cell , immunology , cytomegalovirus infection , intensive care medicine , disease , immunity , human cytomegalovirus , herpesviridae , immune system , viral disease , human immunodeficiency virus (hiv) , virus , biology , genetics
Cytomegalovirus (CMV) viraemia continues to be a frequent complication in the post‐haemopoietic stem cell transplantation period despite a low incidence of CMV end‐organ disease. Several significant advances in the understanding and management of CMV infection have occurred in the last few years including improved diagnostics, monitoring of CMV immunity, availability of novel anti‐CMV drugs, and emerging use of immunotherapies including CMV‐specific T‐cell infusions. In addition to reviewing these advances we also explore some of the more practical prescribing issues of the older and newer CMV drugs including cost, toxicity and drug interactions to help clinicians navigate this new era of CMV management.